Automated sample preparation of Roxifiban tablets: transfer of a manual method to an automated workstation

被引:10
作者
Shamrock, WF [1 ]
Reilly, K [1 ]
Lloyd, DK [1 ]
机构
[1] Dupont Merck Pharmaceut Co, Expt Stn, Pharmaceut R&D, Wilmington, DE 19880 USA
关键词
automation; roxifiban; method development; robotic sample preparation;
D O I
10.1016/S0731-7085(99)00232-0
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Automation offers obvious advantages for the preparation of tablets prior to analysis by HPLC including unattended operation, minimization of human intervention and an electronic audit trail. However, significant effort has to be put in up front to develop and validate an automated method, particularly if it is required to closely follow an existing manual method. Here, method transfer for Roxifiban, a fibrinogen receptor antagonist, will be discussed. A Zymark tablet processing workstation II (TPWII) was used for all automated sample preparations. Manual methods for composite assay, content uniformity, weight variation and degradation products testing of a tablet formulation were transferred to the TPWII. The method involved weighing of the sample, disintegration of the dosage form by homogenization, extraction of the analyte in the homogenate solution, filtration of the homogenate, dilution of the filtrate and transfer to autosampler vials. Obstacles to a quick transfer included limitations in the volume capabilities of the TPWII, poor analyte solubility and achieving proper conditioning of the transfer lines and filter. After resolving these issues, a validated method was achieved. Spiked recoveries were from 99.4 to 101.1% (RSD's <0.5%). A cross-validation between automated and manual assay methods was compared by Westlake analysis giving a 0.7% calculated interval at the 95% confidence level. Carryover was 0.07% after 20 sample preparations at the highest tablet strength. (C) 2000 DuPont Pharmaceuticals Company.
引用
收藏
页码:1225 / 1232
页数:8
相关论文
共 5 条
[1]   Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: Receptor binding affinity and specificity [J].
Mousa, SA ;
Forsythe, M ;
Lorelli, W ;
Bozarth, J ;
Xue, CB ;
Wityak, J ;
Sielecki, TM ;
Olson, RE ;
DeGrado, W ;
Kapil, R ;
Hussain, M ;
Wexler, R ;
Thoolen, MJ ;
Reilly, TM .
CORONARY ARTERY DISEASE, 1996, 7 (10) :767-774
[2]  
TOMLINSON JJ, 1996, DEV VALIDATION ANAL, P185
[3]   SYMMETRICAL CONFIDENCE-INTERVALS FOR BIOEQUIVALENCE TRIALS [J].
WESTLAKE, WJ .
BIOMETRICS, 1976, 32 (04) :741-744
[4]  
Westlake WJ, 1988, BIOPHARMACEUTICAL ST, P329
[5]   The chiral specific synthesis of DMP 754, a platelet GP IIb/IIIa antagonist [J].
Zhang, LH ;
Anzalone, L ;
Ma, P ;
Kauffman, GS ;
Storace, L ;
Ward, R .
TETRAHEDRON LETTERS, 1996, 37 (26) :4455-4458